These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 26648749)

  • 21. Systematic Review with Network Meta-Analysis: Comparative Efficacy of Biologics in the Treatment of Moderately to Severely Active Ulcerative Colitis.
    Vickers AD; Ainsworth C; Mody R; Bergman A; Ling CS; Medjedovic J; Smyth M
    PLoS One; 2016; 11(10):e0165435. PubMed ID: 27776175
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Safety Profile of Biologic Drugs in the Therapy of Ulcerative Colitis: A Systematic Review and Network Meta-Analysis.
    Moćko P; Kawalec P; Pilc A
    Pharmacotherapy; 2016 Aug; 36(8):870-9. PubMed ID: 27312826
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients.
    Schmidt KJ; Herrlinger KR; Emmrich J; Barthel D; Koc H; Lehnert H; Stange EF; Fellermann K; Büning J
    Aliment Pharmacol Ther; 2013 Jan; 37(1):129-36. PubMed ID: 23121200
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Promising biological therapies for ulcerative colitis: A review of the literature.
    Akiho H; Yokoyama A; Abe S; Nakazono Y; Murakami M; Otsuka Y; Fukawa K; Esaki M; Niina Y; Ogino H
    World J Gastrointest Pathophysiol; 2015 Nov; 6(4):219-27. PubMed ID: 26600980
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacotherapy of ulcerative colitis - current status and emerging trends.
    Ahmad H; Kumar VL
    J Basic Clin Physiol Pharmacol; 2018 Nov; 29(6):581-592. PubMed ID: 30089097
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Allogeneic mesenchymal stromal cells in patients with ulcerative colitis: two years of observation].
    Lazebnik LB; Kniazev OV; Konopliannikov AG; Parfenov AI; Ruchkina IN; Mikhaĭlova ZF; Tsaregorodtseva TM; Khomeriki SG; Rogozina VA; Gudkova RB; Shcherbakov PL; Konopliannikova OA
    Eksp Klin Gastroenterol; 2010; (11):3-15. PubMed ID: 21485508
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Methotrexate in ulcerative colitis: a nationwide retrospective cohort from the Veterans Affairs Health Care System.
    Khan N; Abbas AM; Moehlen M; Balart L
    Inflamm Bowel Dis; 2013 Jun; 19(7):1379-83. PubMed ID: 23542534
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review article: the management of steroid dependency in ulcerative colitis.
    Bianchi Porro G; Cassinotti A; Ferrara E; Maconi G; Ardizzone S
    Aliment Pharmacol Ther; 2007 Sep; 26(6):779-94. PubMed ID: 17767462
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Golimumab for the treatment of ulcerative colitis.
    Löwenberg M; de Boer NKh; Hoentjen F
    Clin Exp Gastroenterol; 2014; 7():53-9. PubMed ID: 24648749
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging Treatment Options in Mild to Moderate Ulcerative Colitis.
    Lichtenstein GR; Hanauer SB; Sandborn WJ
    Gastroenterol Hepatol (N Y); 2015 Mar; 11(3 Suppl 1):1-16. PubMed ID: 26491415
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Observational study on the efficacy of adalimumab for the treatment of ulcerative colitis and predictors of outcome.
    García-Bosch O; Gisbert JP; Cañas-Ventura A; Merino O; Cabriada JL; García-Sánchez V; Gutiérrez A; Nos P; Peñalva M; Hinojosa J; García-Planella E; Muñoz F; Calvet X; Panés J
    J Crohns Colitis; 2013 Oct; 7(9):717-22. PubMed ID: 23142005
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis of infliximab, adalimumab, golimumab and vedolizumab for moderate to severe ulcerative colitis in Spain.
    Trigo-Vicente C; Gimeno-Ballester V; Montoiro-Allué R; López-Del Val A
    Expert Rev Pharmacoecon Outcomes Res; 2018 Jun; 18(3):321-329. PubMed ID: 29192530
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-TNF-A Therapy about Infliximab and Adalimamab for the Effectiveness in Ulcerative Colitis Compared with Conventional Therapy: A Meta-Analysis.
    Zhou Z; Dai C; Liu WX
    Hepatogastroenterology; 2015 Jun; 62(140):829-37. PubMed ID: 26902011
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclosporine A for induction of remission in severe ulcerative colitis.
    Shibolet O; Regushevskaya E; Brezis M; Soares-Weiser K
    Cochrane Database Syst Rev; 2005 Jan; (1):CD004277. PubMed ID: 15674937
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Assessment of Long-Term Efficacy and Safety of Adalimumab in Patients with Ulcerative Colitis: Results from a 6-Year Real-World Clinical Practice.
    Sugimoto K; Ikeya K; Kato M; Matsuura A; Watanabe F; Takano R; Tamura S; Tani S; Osawa S; Hanai H
    Dig Dis; 2019; 37(1):11-20. PubMed ID: 30205400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Mucosal Healing in Ulcerative Colitis: A Comprehensive Review.
    Boal Carvalho P; Cotter J
    Drugs; 2017 Feb; 77(2):159-173. PubMed ID: 28078646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Methotrexate Is Not Superior to Placebo for Inducing Steroid-Free Remission, but Induces Steroid-Free Clinical Remission in a Larger Proportion of Patients With Ulcerative Colitis.
    Carbonnel F; Colombel JF; Filippi J; Katsanos KH; Peyrin-Biroulet L; Allez M; Nachury M; Novacek G; Danese S; Abitbol V; Bossa F; Moreau J; Bommelaer G; Bourreille A; Fumery M; Roblin X; Reinisch W; Bouhnik Y; Brixi H; Seksik P; Malamut G; Färkkilä M; Coulibaly B; Dewit O; Louis E; Deplanque D; Michetti P; Sarter H; Laharie D; ;
    Gastroenterology; 2016 Feb; 150(2):380-8.e4. PubMed ID: 26632520
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost per remission and cost per response with infliximab, adalimumab, and golimumab for the treatment of moderately-to-severely active ulcerative colitis.
    Toor K; Druyts E; Jansen JP; Thorlund K
    J Med Econ; 2015 Jun; 18(6):437-46. PubMed ID: 25629655
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Methotrexate Is Not Superior to Placebo in Maintaining Steroid-Free Response or Remission in Ulcerative Colitis.
    Herfarth H; Barnes EL; Valentine JF; Hanson J; Higgins PDR; Isaacs KL; Jackson S; Osterman MT; Anton K; Ivanova A; Long MD; Martin C; Sandler RS; Abraham B; Cross RK; Dryden G; Fischer M; Harlan W; Levy C; McCabe R; Polyak S; Saha S; Williams E; Yajnik V; Serrano J; Sands BE; Lewis JD;
    Gastroenterology; 2018 Oct; 155(4):1098-1108.e9. PubMed ID: 29964043
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Similar Clinical and Surgical Outcomes Achieved with Early Compared to Late Anti-TNF Induction in Mild-to-Moderate Ulcerative Colitis: A Retrospective Cohort Study.
    Ma C; Beilman CL; Huang VW; Fedorak DK; Wong K; Kroeker KI; Dieleman LA; Halloran BP; Fedorak RN
    Can J Gastroenterol Hepatol; 2016; 2016():2079582. PubMed ID: 27478817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.